Mobile

A Phase 2, Randomized, Open-Label trial of GS-9256 plus GS-9190 alone and in combination with Ribavirin for 28 days in Treatment Naive Subjects with Chronic Genotype 1 Hepatitis C Virus Infection

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-013690-18

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objectives of this study are as follows: • To describe the antiviral efficacy of GS 9256 plus GS 9190 alone and in combination with ribavirin (RIBA) against genotype 1 hepatitis C virus (HCV), as measured by the percentage of subjects achieving rapid virologic response (RVR; that is HCV RNA undetectable at Day 28). • To evaluate the safety and tolerability of GS 9256 plus GS 9190 alone and in combination with RIBA for 28 days in subjects with chronic genotype 1 HCV infection.

Critère d'inclusion

  • Chronic hepatitis C virus infection

Liens